The activation of the pathway has been first described in T-cell acute lymphoblastic leukemia (T-ALL), where more than 50% of patients present hyperactivating mutation of Notch1 genes [9]. This evidence concerns the gene NOTCH1 and acute lymphoblastic leukemia.